Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Skin and soft tissue infections; Uncomplicated urinary tract infections 250 mg 6 hourly or 500 mg 12 hourly. Max: 4,000 mg/day in 2-4 divided doses. Respiratory tract infections; Bone and joint infections; Genitourinary infections; Acute prostatitis; Acute dental infections 1,000-4,000 mg/day in divided doses; most infections respond to 500 mg 8 hourly. Streptococcal pharyngitis 250 mg 6 hourly or 500 mg 12 hourly for at least 10 days. Max: 4,000 mg/day in divided doses.
May be taken with or without food. May be taken w/ meals to reduce GI discomfort.
Hypersensitivity to cephalosporins. Acute porphyria.
Special Precautions
Patients with history of carbapenem or penicillin allergy (especially IgE-mediated reactions), and seizure disorder. Children. Renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor renal function tests, LFTs, and CBC periodically with prolonged therapy; monitor for signs of anaphylaxis during 1st dose. Monitor prothrombin time with patient at risk (e.g. nutritionally-deficient patients, prolonged treatment, hepatic or renal impairment).
Adverse Reactions
Significant: Hypersensitivity (rash, urticaria, angioedema, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis), diarrhoea, seizures (in patient with renal impairment), acute intravascular haemolysis, elevated INR. Blood and lymphatic system disorders: Eosinophilia, neutropenia, thrombocytopenia, haemolytic anaemia. Gastrointestinal disorders: Dyspepsia, abdominal pain, gastritis, nausea, vomiting. General disorders and administration site conditions: Fatigue, fever. Hepatobiliary disorders: Rarely, transient hepatitis, cholestatic jaundice. Investigations: Slightly elevated AST and ALT. Musculoskeletal and connective tissue disorders: Arthralgia, arthritis. Nervous system disorders: Headache, dizziness. Psychiatric disorders: Agitation, confusion, hallucinations, nervousness, hyperactivity. Renal and urinary disorders: Interstitial nephritis (reversible). Reproductive system and breast disorders: Genital and anal pruritus, vaginitis, genital moniliasis and candidiasis, vaginal discharge.
Potentially Fatal: Anaphylaxis, Clostridium difficile-associated diarrhoea (CDAD).
Drug Interactions
Renal excretion may be inhibited by probenecid resulting to increased plasma concentration of cefalexin. May increase plasma concentration of metformin. Increased risk of nephrotoxicity with amphotericin, loop diuretics, aminoglycoside, capreomycin or vancomycin. May increase risk of hypokalaemia with gentamicin (in patient taking cytotoxic drugs for leukaemia). May decrease efficacy of oestrogen-containing oral contraceptives.
CIMS Class
ATC Classification
J01DB01 - cefalexin ; Belongs to the class of first-generation cephalosporins. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on cefalexin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in